申请人:Wuhan Shengyun Biopharma Co., Ltd.
公开号:US20140371221A1
公开(公告)日:2014-12-18
The present invention relates to a quinoline derivative represented by general formula (I) or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof wherein Ar, R
1
, R
2
, R
3
, X, Y and n have the meanings given in the description. The present invention also relates to the comparatively strong effect of the compound represented by general formula (I) on inhibiting c-Met kinase. The present invention further relates to the use of this compound or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof in the manufacturing of a medicament for treating the disease caused by abnormally over-expressing c-Met kinase, in particular, for treating or preventing cancer.
本发明涉及一种喹啉衍生物,其由通式(I)表示或其药学上可接受的盐、水合物、溶剂化物或前药,其中Ar、R1、R2、R3、X、Y和n的含义如说明书所述。本发明还涉及通式(I)所表示的化合物对抑制c-Met激酶的相对强效作用。本发明还涉及使用该化合物或其药学上可接受的盐、水合物、溶剂化物或前药制造用于治疗由异常高表达c-Met激酶引起的疾病的药物,特别是用于治疗或预防癌症。